These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1172 related items for PubMed ID: 23184081

  • 1. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N, Mukai H, Fujii S, Wada N.
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [Abstract] [Full Text] [Related]

  • 2. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz RM.
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H.
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y.
    J BUON; 2013 Mar; 18(1):57-63. PubMed ID: 23613389
    [Abstract] [Full Text] [Related]

  • 10. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L, Morabito F, Provinciali N, Canobbio L, Meszaros P, Naso C, Murialdo R, Boitano M, Salvi S, Ferrarini M.
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.
    Int J Clin Exp Pathol; 2014 Oct; 7(10):6862-70. PubMed ID: 25400769
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.
    Oncology; 2011 Oct; 80(3-4):269-77. PubMed ID: 21734419
    [Abstract] [Full Text] [Related]

  • 15. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
    Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N.
    Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
    [Abstract] [Full Text] [Related]

  • 16. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R.
    Oncology; 2011 Oct; 80(5-6):341-9. PubMed ID: 21791944
    [Abstract] [Full Text] [Related]

  • 17. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.
    Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G.
    Clin Breast Cancer; 2010 Jun; 10(3):230-7. PubMed ID: 20497922
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM.
    Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
    [Abstract] [Full Text] [Related]

  • 19. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 20. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
    Glück S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G.
    Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.